• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Is the transverse colon the new right?-similarities in EGFR drug response and prognosis.

作者信息

Cameselle-García Soledad, Fernández Montes Ana

机构信息

Gastrointestinal Cancer Unit, Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, Ourense, Spain.

出版信息

J Gastrointest Oncol. 2024 Oct 31;15(5):2363-2366. doi: 10.21037/jgo-24-272. Epub 2024 Oct 10.

DOI:10.21037/jgo-24-272
PMID:39554581
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11565101/
Abstract
摘要

相似文献

1
Is the transverse colon the new right?-similarities in EGFR drug response and prognosis.横结肠是新的“右侧”吗？——表皮生长因子受体（EGFR）药物反应及预后方面的相似性
J Gastrointest Oncol. 2024 Oct 31;15(5):2363-2366. doi: 10.21037/jgo-24-272. Epub 2024 Oct 10.
2
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.表皮生长因子受体基因扩增和 PTEN 蛋白表达是 KRAS 野生型转移性结直肠癌患者接受西妥昔单抗治疗的有利预后因素。
J Cancer Res Clin Oncol. 2014 May;140(5):737-48. doi: 10.1007/s00432-014-1626-2. Epub 2014 Mar 5.
3
Autocrine growth stimulation of SW403 colon carcinoma cell line is caused by transforming-growth-factor-alpha-mediated epidermal growth factor receptor activation.SW403结肠癌细胞系的自分泌生长刺激是由转化生长因子-α介导的表皮生长因子受体激活所引起的。
J Cancer Res Clin Oncol. 1996;122(6):328-34. doi: 10.1007/BF01220799.
4
Interpretation of Epidermal Growth Factor Receptor Status in Microscopic Tumor-Free Surgical Margins and Lymph Nodes in Patients with Oral Squamous Cell Carcinoma: An Analysis of 125 Margins.口腔鳞状细胞癌患者无肿瘤微小手术切缘和淋巴结中表皮生长因子受体状态的解读：125例切缘分析
J Maxillofac Oral Surg. 2024 Aug;23(4):873-880. doi: 10.1007/s12663-024-02263-9. Epub 2024 Jul 1.
5
Mechanism of the epidermal growth factor receptor in promoting endothelial cell dysfunction in gestational diabetes mellitus.表皮生长因子受体在妊娠期糖尿病中促进内皮细胞功能障碍的机制
World J Diabetes. 2025 Jun 15;16(6):105173. doi: 10.4239/wjd.v16.i6.105173.
6
Comprehensive analysis of single-cell and bulk RNA sequencing data reveals an EGFR signature for predicting immunotherapy response and prognosis in pan-cancer.单细胞和批量RNA测序数据的综合分析揭示了一种用于预测泛癌免疫治疗反应和预后的EGFR特征。
Front Immunol. 2025 Jun 12;16:1604394. doi: 10.3389/fimmu.2025.1604394. eCollection 2025.
7
Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials.横结肠癌原发灶位置作为转移性结直肠癌的生物标志物：CCTG/AGITG CO.17 和 CO.20 随机临床试验的汇总分析。
Clin Cancer Res. 2024 Mar 15;30(6):1121-1130. doi: 10.1158/1078-0432.CCR-23-3275.
8
Expression of nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues.核干细胞因子、表皮生长因子及其受体在人食管鳞状细胞癌组织中的表达。
J Cancer Res Clin Oncol. 2010 Apr;136(4):587-94. doi: 10.1007/s00432-009-0693-2. Epub 2009 Oct 13.
9
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.辅助性表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）用于治疗已切除的Ⅰ至Ⅲ期非小细胞肺癌且伴有EGFR突变的患者。
Cochrane Database Syst Rev. 2025 May 27;5(5):CD015140. doi: 10.1002/14651858.CD015140.pub2.
10
Growth-promoting effect of muscarinic acetylcholine receptors in colon cancer cells.毒蕈碱型乙酰胆碱受体在结肠癌细胞中的促生长作用。
J Cancer Res Clin Oncol. 2003 May;129(5):272-8. doi: 10.1007/s00432-003-0433-y. Epub 2003 May 14.

本文引用的文献

1
Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials.横结肠癌原发灶位置作为转移性结直肠癌的生物标志物：CCTG/AGITG CO.17 和 CO.20 随机临床试验的汇总分析。
Clin Cancer Res. 2024 Mar 15;30(6):1121-1130. doi: 10.1158/1078-0432.CCR-23-3275.
2
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.帕尼单抗联合贝伐珠单抗对比标准一线化疗方案联合贝伐珠单抗用于 RAS 野生型、左侧转移性结直肠癌患者的生存获益：一项随机临床试验。
JAMA. 2023 Apr 18;329(15):1271-1282. doi: 10.1001/jama.2023.4428.
3
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials.
在RAS野生型转移性结直肠癌患者中，原发肿瘤部位作为治疗选择的驱动因素：一项随机试验的系统评价和汇总分析
Eur J Cancer. 2023 May;184:106-116. doi: 10.1016/j.ejca.2023.02.006. Epub 2023 Feb 17.
4
Targeting KRAS in colorectal cancer: the beginning of a new era.结直肠癌中 KRAS 的靶向治疗：新时代的开端。
ESMO Open. 2023 Feb;8(1):100745. doi: 10.1016/j.esmoop.2022.100745. Epub 2022 Dec 20.
5
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated G12C.在携带突变 G12C 的结直肠癌中，阿达格拉西布联合或不联合西妥昔单抗。
N Engl J Med. 2023 Jan 5;388(1):44-54. doi: 10.1056/NEJMoa2212419. Epub 2022 Dec 21.
6
Time-varying prognostic value of primary tumor sidedness in metastatic colorectal cancer: A population-based study and meta-analysis.原发肿瘤侧别在转移性结直肠癌中的时变预后价值：基于人群的研究和荟萃分析。
Int J Cancer. 2023 Apr 1;152(7):1360-1369. doi: 10.1002/ijc.34347. Epub 2022 Nov 30.
7
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.转移性结直肠癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2023 Jan;34(1):10-32. doi: 10.1016/j.annonc.2022.10.003. Epub 2022 Oct 25.
8
Prognostic Value of Mutations in Colorectal Cancer Patients.结直肠癌患者基因突变的预后价值
Cancers (Basel). 2022 Jul 7;14(14):3320. doi: 10.3390/cancers14143320.
9
Sotorasib for previously treated colorectal cancers with KRAS mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.索托拉西布治疗 KRAS 突变的既往治疗过的结直肠癌（CodeBreaK100）：一项单臂、2 期试验的预先指定分析。
Lancet Oncol. 2022 Jan;23(1):115-124. doi: 10.1016/S1470-2045(21)00605-7. Epub 2021 Dec 15.
10
Right and left-sided colon cancers - specificity of molecular mechanisms in tumorigenesis and progression.左右侧结肠癌——肿瘤发生和发展中分子机制的特异性。
BMC Cancer. 2020 Apr 15;20(1):317. doi: 10.1186/s12885-020-06784-7.